Cat. No.: HY-174979

Dac590

Customer Review

Based on 1 Customer Validation

Dac590 is an orally active and selective obesity-associated protein (FTO) inhibitor with an IC₅₀ of 6.06 nM. Dac590 shows highly selective over ALKBH5 and ALKBH3. Dac590 suppresses oncogenic FTO signaling, induces myeloid differentiation, G1-phase cell cycle arrest, and apoptosis in acute myeloid leukemia (AML) cells. Dac590 inhibits xenograft tumor growth and prolongs survival in acute myeloid leukemia mouse models with no observed toxicity. Dac590 can be used for the research of AML.

For research use only. We do not sell to patients.

Purity: 96.15%
CAS No.: 3084407-00-8
Formula: C₁₉H₁₆ClFN₂O₄
Molecular Weight:390.79

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Dac590 Chemical Structure

CAS No.: 3084407-00-8

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

In Vitro

Dac590 (20 μM) completely inhibits recombinant FTO demethylase activity at a concentration of 20 μM^[1].
Dac590 (0-1 μM; 0-48 h) increases global m⁶A RNA methylation levels in a time- and dose-dependent manner in NB4 and MOLM-13 AML cells^[1].
Dac590 (0.2-5 μM) modulates FTO downstream oncogenic pathways in NB4 and MOLM-13 AML cells, upregulating ASB2 and RARA expression while downregulating c-MYC and CEBPA^[1].
Dac590 (0.5-1 μM; 48 h) induces myeloid differentiation in NB4 and MOLM-13 AML cells, as measured by increased CD11b expression^[1].
Dac590 (1 μM; 48 h) induces G1-phase cell cycle arrest in NB4 and MOLM-13 AML cells^[1].
Dac590 (0.2-2 μM; 48 h) induces dose-dependent apoptosis in NB4 and MOLM-13 AML cells^[1].
Dac590 (0-1 μM; 48 h) reduces DNMT1 protein levels in NB4 and MOLM-13 AML cells^[1].
Dac590 (72 h) inhibits the proliferation of NB4, MOLM-13, NOMO-1, MV-4-11, HEL, U937, K562, and MONO-MAC-6 cells with IC₅₀s of 327.7, 358.3, 1405, 506.1, 507.6, 845.1, 1191, 596.5 nM, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Differentiation Assay^[1]

Cell Line:

NB4 and MOLM-13 AML cells
Concentration:

0.5, 1 μM
Incubation Time:

48 h
Result:

Increased CD11b mean fluorescence intensity in both cell lines, indicating induction of myeloid differentiation.
Induced myeloid differentiation in NB4 and MOLM-13 AML cells.

Cell Cycle Analysis^[1]

Cell Line:

NB4 and MOLM-13 AML cells
Concentration:

1 μM
Incubation Time:

48 h
Result:

Caused G1-phase cell cycle arrest in both cell lines, increasing the percentage of cells in G0/G1 phase and decreasing the percentage in S and G2/M phases.

Apoptosis Analysis^[1]

Cell Line:

NB4 and MOLM-13 AML cells
Concentration:

0.2, 0.5, 1, 2 μM
Incubation Time:

48 h
Result:

Induced apoptosis in a dose-dependent manner in both cell lines, increasing the percentage of Annexin V+/PI- and Annexin V+/PI+ cells.

Western Blot Analysis^[1]

Cell Line:

NB4 and MOLM-13 AML cells
Concentration:

0, 0.2, 0.5, 1 μM
Incubation Time:

48 h
Result:

Reduced DNMT1 protein levels in both cell lines, with a particularly strong effect in MOLM-13 cells.
Increased ASB2 and RARA levels.
Downregulated c-MYC and CEBPA levels.

Parmacokinetics

Species	Dose	Route	T_1/2	T_max	C_max	AUC_0-t	Bioavailability
Mice^[1]	1 mg/kg	i.v.	3.77 h	0.08 h	4340 ng/mL	6079 ng·h/mL	/
Mice^[1]	2 mg/kg	i.g.	5.81 h	0.08 h	3970 ng/mL	7276 ng·h/mL	61.1 %

In Vivo

Dac590 (25 and 40 mg/kg; i.g.; daily; 20 days) significantly prolongs survival and inhibits tumor growth in mouse MOLM-13 AML models^[1].
Dac590 (40 mg/kg; i.g.; daily; 28 days) shows no observable toxicity in female BALB/c mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female NSG mice (6 weeks old) intravenously injected wiht MOLM-13 cells, followed 20 mg/kg Busulfan (HY-B0245) pretreatment 24 hours prior^[1]
Dosage:

25, 40 mg/kg
Administration:

i.g.; daily; 20 days
Result:

Significantly prolonged survival compared to vehicle control.
Showed no adverse effects on body weight.
Enhanced survival benefit when combined with Decitabine (DAC) (HY-A0004) .

Animal Model:

Female BALB/c mice (6-8 weeks old)^[1]
Dosage:

40 mg/kg
Administration:

i.g.; daily; 28 days
Result:

Showed no significant body weight changes compared to vehicle controls.
Detected no pathological changes in heart, liver, spleen, lungs, or kidneys via H&E staining.

Chemical Information

CAS No. 3084407-00-8
Appearance Solid
Molecular Weight 390.79
Formula C₁₉H₁₆ClFN₂O₄
Color Yellow to brown
SMILES

OC(C1=CC(OC)=CC=C1NC2=C(C=C(C=C2Cl)C3=C(ON=C3C)C)F)=O
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 12.5 mg/mL (31.99 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5589 mL

12.7946 mL

25.5892 mL

5 mM

0.5118 mL

2.5589 mL

5.1178 mL

10 mM

0.2559 mL

1.2795 mL

2.5589 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Yang T, et al. Development of Orally Bioavailable FTO Inhibitors with Potent Antileukemia Efficacy. J Med Chem. 2025;68(13):13714-13727. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5589 mL	12.7946 mL	25.5892 mL	63.9730 mL
	5 mM	0.5118 mL	2.5589 mL	5.1178 mL	12.7946 mL
	10 mM	0.2559 mL	1.2795 mL	2.5589 mL	6.3973 mL
	15 mM	0.1706 mL	0.8530 mL	1.7059 mL	4.2649 mL
	20 mM	0.1279 mL	0.6397 mL	1.2795 mL	3.1986 mL
	25 mM	0.1024 mL	0.5118 mL	1.0236 mL	2.5589 mL
	30 mM	0.0853 mL	0.4265 mL	0.8530 mL	2.1324 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Dac590

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Orally Active Compound Library

Anti-Blood Cancer Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Dac590

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Orally Active Compound Library

Anti-Blood Cancer Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Dac590 Related Classifications

HY-174979 Related Classifications